GODAVARI DRUGS LTD.

Godavari Drugs Limited's Board of Directors, in a meeting held on October 14, 2026, approved availing working capital limits of up to ₹340 Million (₹34 Crore) from ICICI Bank Limited. The approval includes a temporary overdraft facility and creation of security as stipulated by the bank. Mr. Mukund Kakani, Managing Director, has been authorized to finalize and execute the necessary documentation. These facilities fall within the borrowing limits previously approved by the company's members.

Godavari Drugs Ltd has announced the closure of its trading window for designated persons and their immediate relatives, effective October 1, 2026. This closure is in accordance with SEBI regulations and the company's code of conduct, and is necessary for the consideration and approval of the unaudited financial results for the quarter and half-year ended September 30, 2026. The exact date of the board meeting to approve these financials will be communicated later. During the trading window closure, no trading in the company's securities is permitted for insiders.

Godavari Drugs Ltd has dispatched physical letters to shareholders whose email addresses are not registered, providing a weblink and QR code to access the Notice for the Annual General Meeting (AGM). The AGM is scheduled for Friday, September 25, 2026, at 03:00 p.m. through Video Conferencing/Other Audio-Visual Means. The letter informs shareholders about the AGM notice availability on the company's website and the BSE website. Key AGM details include the meeting date, cut-off date for eligibility, and electronic voting periods. Shareholders are urged to update their email addresses for future electronic communication.

Godavari Drugs Ltd has announced that its 38th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 3:00 PM IST via Video Conferencing. The company will also submit its Annual Report for FY 2025-26 and the Notice of the 38th AGM. Key dates include a cut-off date of September 18, 2026, for determining shareholder eligibility for remote e-voting, and the closure of the Register of Members from September 19 to September 25, 2026. Remote e-voting will be open from September 22 to September 24, 2026.

Godavari Drugs Ltd has announced that its Register of Members and Share Transfer Books will be closed from September 19, 2026, to September 25, 2026, inclusive. This closure is for the purpose of the 38th Annual General Meeting (AGM) scheduled for September 25, 2026. The company has also fixed September 18, 2026, as the cut-off date for determining shareholders eligible for remote e-voting. The e-voting period will commence on September 22, 2026, and conclude on September 24, 2026.

Godavari Drugs Ltd has announced its 38th Annual General Meeting (AGM) will be held on September 25, 2026, at 3:00 PM IST. The meeting will be conducted via Video Conferencing/Other Audio Visual Means, adhering to MCA and SEBI circulars. The company is also submitting its Annual Report for FY 2025-26 along with the AGM notice. Key dates include a cut-off date of September 18, 2026, for shareholder eligibility for remote e-voting, with the register of members closed from September 19 to September 25, 2026. Remote e-voting will be open from September 22 to September 24, 2026.

Godavari Drugs Limited's Board of Directors has approved an amendment to the company's Memorandum of Association (MOA). The key change involves inserting a new main object clause to include the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products. This expansion aims to allow the company to formally engage in domestic and export marketing, contract manufacturing, and own manufacturing within this growing sector. The amendment is subject to shareholder approval via a Special Resolution at the upcoming 38th Annual General Meeting (AGM) scheduled for September 25, 2026, and subsequent filing with the Ministry of Corporate Affairs. The alteration is additive and does not affect existing business or shareholder rights.

Godavari Drugs Limited's Board of Directors, in a meeting held on August 31, 2026, approved the alteration of the Memorandum of Association to include a new main object for the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products. This expansion aims to leverage domestic and export markets for manufacturing and marketing these products. The change requires shareholder approval via a Special Resolution at the upcoming 38th Annual General Meeting scheduled for September 25, 2026. The alteration is additive and does not affect existing business or shareholder rights.

Godavari Drugs Ltd has submitted its Statement on Deviation or Variation in Utilisation of Funds for the quarter ended June 30, 2026. This statement was reviewed and approved by the Board of Directors during their meeting on August 14, 2026. The company has filed this statement along with the outcome of the board meeting with the stock exchange for information and record purposes. The filing adheres to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Godavari Drugs Ltd announced the allotment of 7,86,690 equity shares following the conversion of warrants. This conversion was approved by the Board of Directors on August 14, 2026. The shares were issued on a preferential basis to the 'Promoters Category' at an issue price of ₹89 per share, including a premium of ₹10. The company received the balance 75% of the issue price, amounting to ₹5,25,11,557.5, from the allottees. This allotment increases the company's paid-up equity capital from ₹10,12,74,350 to ₹10,91,41,250. The new shares rank pari-passu with existing equity shares. A total of 15,73,375 warrants remain outstanding for conversion.